GSK Recalls ‘Alli’ Drug Due To ‘Drugs In Wrong Bottle’ Mix Up!…

Andrew Witty! CEO of The Year!...
Reminds me of the Cheryl Eckard Scandal...–finance.html


The GlaxoSmithKline logo is seen at the entrance of a building in Luxembourg

By Ben Hirschler

 LONDON (Reuters) – GlaxoSmithKline is recalling all supplies of its non-prescription weight-loss drug Alli in the United States and Puerto Rico after customers reported finding other pills and tablets in some bottles.

The news is a fresh blow for a product once touted as a potential blockbuster but which has had disappointing sales over the years – aggravated, in part, by a separate supply problem two years ago.

The British group said it believed that some U.S. bottles of Alli might not contain authentic product, adding that it was working with the U.S. Food and Drug Administration on the retailer-level recall.

News that bottles had been tampered with first emerged on Wednesday.

GSK has received inquiries from consumers in Alabama, Florida, Louisiana, Mississippi, New York, North Carolina and Texas about 20 bottles containing tablets and capsules that were not Alli.

The treatment is also sold in Europe but the company said no problems had been detected there and European sales were not affected by the U.S. recall.

GSK said it was not immediately clear how the bottles had been tampered with or where in the supply chain the problem had occurred.


“The investigation is ongoing. We’ve asked people to return bottles to us, so we can examine them very closely … we don’t have any theories at this point,” a company spokeswoman said.

Shoppers said they had found a range of tablets and capsules of various shapes and colors in purchased Alli containers. The authentic drug is a turquoise-blue capsule. Some bottles inside the outer carton were also missing labels and had tamper-evident seals that were not genuine.

There have been no reports of any serious illnesses related to the product after news of the tampering.

Quality problems have become a big issue in the pharmaceuticals industry, with most attention focused on Indian generic prescription drug suppliers. However, Western groups such as Johnson & Johnson have also suffered failures in quality control.

Alli is marketed by GSK’s consumer healthcare business and is approved for over-the-counter (OTC) sale for overweight adults, in conjunction with a low-fat diet.

The treatment, which is a low-dose version of Roche’s Xenical, was launched in the United States in 2007 with a big marketing campaign. But the product has failed to achieve the $500 million to $1 billion of sales analysts had initially forecast.

GSK no longer breaks out Alli sales figures, though revenue from the product was 93 million pounds ($154 million) in 2011.

The company tried to sell the Alli brand that year, along with a number of other non-core OTC healthcare products, but its divestment was scrapped after an interruption in supplies from Roche, which makes the active ingredient for the drug. ($1 = 0.6037 British Pounds)

(Editing by David Goodman)


John Virapen: Pharmaceutical Insider Exposes SSRI’s And Drug Company Lies


(parts 2,3 and 4 on youtube here)


Paxil (Seroxat/Paroxetine) Causes Breast Cancer

From Mad In America

Paxil Boosts Estrogen, May Promote Breast Cancer Growth

February 20, 2014

A trial of a new process of identifying drugs that can disrupt sex hormones singled out Paxil from 446 common drugs as having a weak estrogenic effect that could promote the growth of breast tumors in women. The study may shed light on previous studies that found women taking Paxil were more likely than those taking other antidepressants to die of breast cancer when also taking tamoxifen to prevent breast cancer recurrence.

Abstract →

Chen, S., Zhou, D., Hsin, L., Kanaya, N., et al; AroER Tri-Screen™ is a Biologically Relevant Assay for Endocrine Disrupting Chemicals Modulating the Activity of Aromatase and/or the Estrogen Receptor. Toxicological Sciences. Online February 4, 2014. doi: 10.1093/toxsci/kfu023

Of further interest:

Antidepressant Paxil boosts estrogen activity, new study finds (City of Hope)
New test suggests antidepressant Paxil may promote breast cancer (LA Times)
Popular antidepressant linked to increased breast cancer risk (RT)
Study: Paxil Could Promote Breast Tumor Growth In Women (CBS Atlanta)
Possible Link Between Paxil and Breast Cancer Found (Yakkity Yak)
City of Hope Researchers Develop Test to Assess Effect of More Than 1,500 Chemicals on Estrogen(Newswise)

Andrew Witty: Transparency and Ethical Behavior? ..

Perhaps if you dis-count murdering your customers with drugs like Seroxat and Avandia!.. but even at that, GSK’s history and behavior leaves a lot to be desired.. as far as ethics and transparency are concerned GSK has a long long way to go… that said, Andrew Witty is very good at generating good PR (although PR stunts are hardly indicators of real ethics and change) he should certainly be applauded for that.. but with his immense salary, his dedication to protecting the image of his paymasters is pretty much a given…


4:34 am
Mar 21, 2014


The Perfect U.K. CEO? Glaxo’s Andrew Witty, Apparently

GlaxoSmithKline’sAndrew Witty

By Peter Evans

It’s a result to rival that of any North Korean election. Andrew Witty, chief executive at drug maker GlaxoSmithKlineGSK.LN -0.83%, has been voted the U.K.’s top chief executive in a new poll from careers site Glassdoor. His approval rating? 100%.

Glassdoor asked employees in the U.K. to approve or disapprove of the way their CEO leads the company. A minimum of 20 votes were required for ranking consideration, and voters remained anonymous.

Witty, Glaxo’s CEO since 2008, received unanimous approval on his performance, with one excited voter saying his boss had created a “strong work culture based on transparency and ethical behavior.”

Glaxo last month posted a 20% increase in full-year profit, despite its ongoing involvement in a bribery scandal in China. The company on Thursday reporteddisappointing late-stage trial results on an experimental cancer vaccine.

A Glaxo spokesman declined to comment on the poll.

Joe Wiggins, a spokesman for Glassdoor, said the site had calculated Witty’s flawless rating using a “proprietary algorithm” to collate employee feedback.

“It’s fairly rare to get a 100% approval rating, but it does happen,” Wiggins said.

Second and third on the list, each with a disappointing 97% approval—similar to the proportion of voters in Crimea who supported becoming part of Russia—were Rolls Royce Holdings’ John Rishton and Charlie Mayfield, CEO at upmarket retailer John Lewis Partnership. Rishton came out slightly ahead, but Glassdoor rounded the reported percentages, Wiggins said.

The full top 10:

1. Andrew Witty, GlaxoSmithKline – 100%

Idiot Of The Day: Dr Chris Steele


Idiot Of The Day: Dr Chris Steele 

Very little explanation needed as to why Dr. Chris Steele has been selected as the first- Idiot of the day post on my blog. This doctor takes anti-depressants himself and more or less thinks that they are like smarties and we should all be necking them down our throats without a second thought. He also prescribes to the notion that these drugs should be taken for life, something akin to hormone replacement therapy! How ridiculous is that? Very silly man, and a totally irresponsible idiot. Watch the video and marvel at the sheer idiocy of this well known doctor…

He actually says here “anti-depressants will put you right”..this is dangerous advice and he offers no advice about diet, exercise, therapy or the myriad of reasons why people become depressed, such as loss, grief, psychological difficulties, inability to cope, stress, trauma etc…

Furthermore- he actually believes in the chemical imbalance nonsense too!.. which is fine if he wants to be deluded himself, but there is something disturbing about a doctor promoting a dubious theory which was invented by pharmaceutical companies and has been debunked for ages!..  the mind boggles…

Mick Jagger’s Girlfriend L’Wren Scott Suicide… Were Anti-Depressant Drugs (SSRI’s) Involved?


March 18, 2014

Mick Jagger, front man of the Rolling Stones, has canceled the first show of his Australian tour, after news that his longtime girlfriend, L’Wren Scott committed suicide. Jagger had reportedly just landed in Perth on March 17, 2014, when he received the tragic news that Scott was found, hanging by a scarf from a doorknob inside her Manhattan, NYC apartment. The couple had dated since 2001. This was the first show scheduled for the Rolling Stones; it is unclear when they will resume touring.

A message on the official Rolling Stoneswebsite states that at the current time, there is no further information as to the tour schedule; however, the message asks ticket holders to keep their tickets rather than returning them. This gives the indication that the tour may resume at another date; however, an official confirmation has not been made.

The site message reads as follows, “The Rolling Stones concert in Perth will not be going ahead as scheduled for Wednesday 19 March 2014.

“No further information is available at this time, ticket holders are asked to hold on to their tickets until a further update is available.

“Ticket holders can check back here, at, for official updates.”

Previous reports speculate that Scott’s suicide might have been the result of troubled finances the fashion designer and former model was currently experiencing. The Daily Mailestimated her debt in excess of $6 million. It is unclear whether Scott had sought medical or psychiatric help for depression and if so, whether she had been prescribed anti-depressants. Anti-depressants have a number of side effects, including an increase in suicidal thoughts and attempts in some users. Whether Scott had taken medication or recently switched medication is unknown at this time.

Her death is currently under investigation and official cause of death will be made by the medical examiner’s office. According to current reports, foul play is not suspected.

Our hearts go out to L’Wren Scott’s family, friends and loved ones at this time.

British Penalties for China bribery may be on the way for GSK…

British penalties for China bribery may be on the way for GSK

February 21, 2014 | By 

China has yet to leverage any formal penalties on GlaxoSmithKline ($GSK) for the $489 million bribery scandal that broke there last summer. But punishment may be on the way from GSK’s home base.

On Friday, Britain’s Serious Fraud Office (SFO) told the South China Morning Post that it plans to prosecute or fine some companies for overseas bribery, and some say GSK is likely among them. “We assume this includes GlaxoSmithKline,” Rob Elvin, managing partner of law firm Squire Sanders, told the newspaper.

According to the Post, a new SFO policy unveiled earlier this month will make it faster and easier to deal with overseas bribery cases. A deferred prosecution agreement policy, which allows companies to settle criminal allegations without being prosecuted and without formally admitting guilt, will be available for economic crimes starting Monday.

The Biotech Primer: An insider’s guide to the science driving the biotech and pharma industries

This 200-page book takes an in-depth look at the biotech industry and the science that drives it. Although the industry itself is constantly changing, these fundamental concepts upon which it is built will remain important for years to come – and decision-makers who understand these fundamentals will be better able to evaluate and predict new trends. Click here to buy today!

GSK CEO Andrew Witty

Glaxo, though, has already admitted guilt in China, with emerging markets chief Abbas Hussain identifying “breaches” of Chinese law and offering price cuts as part of an apology to government officials for funneling doctor bribes through travel agencies. CEO Andrew Witty has acknowledged guilt, too, pinning it on “certain senior executives” at GSK China who acted “outside our process and controls.”

Accordingly, Chinese authorities talked openly of imposing “astronomical” fines on the drugmaker back in September. But so far, an 18% pharmaceuticals and vaccines sales hit for 2013 in the country has been GSK’s only monetary penalty, aside from the self-imposed price cuts. In November, Reuters reported that the British pharma giant would likely escape Chinese corruption charges, though its local executives probably wouldn’t.

Aside from British and Chinese probes, Glaxo is currently subject to an investigation in the U.S., where its listed shares make it vulnerable to prosecution for violations of the Foreign Corrupt Practices Act. But Glaxo anticipated as much from the get-go: “Since the investigation in China began, we have proactively reached out to relevant regulators,” spokesman David Mawdsley told Reuters in September. “This includes the DoJ, and we have been in an ongoing dialogue with them.”

– get more from the South China Morning Post

Special Reports: Top 10 Drugmakers in Emerging Markets – GSK | Top Pharma Companies by 2012 Revenues – GSK | The most influential people in biopharma today – Andrew Witty – GlaxoSmithKline

Related Articles:
Reuters: GlaxoSmithKline likely to escape China charges, but execs probably won’t
GlaxoSmithKline’s China probe triggers U.S. bribery investigation
China talks about massive fines against GSK
GlaxoSmithKline exec admits ‘breaches,’ promises price cuts in China
GlaxoSmithKline CEO says HQ, British execs ‘knew nothing’ of China fraud

Read more: British penalties for China bribery may be on the way for GSK – FiercePharma
Subscribe at FiercePharma

Deirdre Connolly (GSK) : “We want to ensure that no one even perceives us to be doing anything wrong.”


Glaxo to Bring Doctors In-House as Educational Speakers

By Makiko Kitamura  Mar 17, 2014 1:09 PM GMT
AprJunAugOctDecFeb1,500.001,600.001,700.001,800.00* Price chart for GLAXOSMITHKLINE PLC. Click flags for important stories.GSK:LN1637.508.00 0.49%1,629.00Mar 17

GlaxoSmithKline Plc (GSK) plans to hire doctors to educate their peers about its drugs instead of paying external speakers, a further change to its marketing practices following a record fraud settlement in the U.S.

The drugmaker is also investing in improving its multichannel marketing strategy through media such as online streaming of educational content, Deirdre Connelly, head of Glaxo’s U.S. pharmaceuticals business, said in an interview in Philadelphia. The changes come at a time when London-based Glaxo is introducing products recently approved to treat skin cancer, HIV and respiratory diseases.

Glaxo has been reforming marketing practices to improve its reputation. In 2012, the company agreed to pay $3 billion to settle allegations that it illegally promoted its Paxil and Wellbutrin anti-depressants and failed to report safety data on the Avandia diabetes drug. Hiring doctors and medical experts to speak as in-house representatives of Glaxo will provide more transparency, Connelly said.

“We’ll continue to disseminate this very important information on drug benefits and risks, but we’re just not going to do that by hiring external speakers,” she said. “We want to ensure that no one even perceives us to be doing anything wrong.”

Customer Evaluations

Glaxo plans to hire a range of people with medical backgrounds, including doctors and scientists with expertise in specific disease areas, though how many is still unclear, according to the company. It will be fewer than the number of external speakers the company has employed, Connelly said. In December, Glaxo said that it will stop paying doctors for giving speeches and attending medical meetings by early 2016.

Connelly started her career as a sales representative at Eli Lilly & Co. (LLY) and rose to lead that company’s U.S. operations. She joined Glaxo in 2009 and was responsible for devising the company’s new compensation model that got rid of the link between sales targets and bonuses. Bonuses are now based on selling competency, customer evaluations and overall performance of the representative’s business unit.

Dubbed “Patient First,” that measure was implemented in the U.S. in 2011. A similar program will be extended to all markets by 2015, Glaxo said in December. The announcement also came amid an ongoing bribery investigation of Glaxo in China.

Hiring internal speakers isn’t a widespread practice in the industry and has pros and cons, said Pratap Khedkar, who runs consulting company ZS Associates’ global pharmaceuticals practice in Philadelphia.

Credibility Question

Because they will be employees of Glaxo, the company won’t have to report payments to doctors under the so-called Sunshine Act in the U.S. that requires such disclosures. On the other hand, their credibility may be questioned, and they won’t be able to answer questions such as how they would treat a patient with specific symptoms or problems, given that they aren’t practicing physicians, Khedkar said.

The Glaxo representatives may be perceived in the same way as so-called medical science liaisons, who typically have pharmacy or nursing degrees and play an educational role in speaking to doctors, such as explaining clinical trial results, Khedkar said.

Opinion Leaders

The corporate ties and a lack of reputation among practicing colleagues may hamper the Glaxo representatives’ sway with physicians, said Erik Gordon, professor at theUniversity of Michigan’s School of Law and Ross School of Business.

“Doctors aren’t influenced by just any other doctor,” Gordon said by e-mail. “They are influenced by doctors who are sufficiently well known, respected, and seen as key opinion leaders — real experts with lots of experience with patients.”

The shift in strategy comes as Glaxo introduces several key new products, including Breo and Anoro for respiratory disease. Breo’s uptake in the U.S. has trailed that of Merck & Co.’s Dulera, which is in the same class of drugs, and were little changed in the week ended March 7, Bloomberg Industries analyst Sam Fazeli said today, citing data from Symphony Health Solutions.

“The real test will be how Anoro gets on,” Fazeli said. Anoro, which will be introduced in the U.S. by the end of April, has higher sales potential than Breo, potentially reaching $1.55 billion in 2017, according to the average of five analyst estimates compiled by Bloomberg.

Instant Replies

Connelly said the experts at Glaxo will be expected to use a growing range of digital tools designed to help market products.

In addition to targeted e-mails and Web seminars, drugmakers are increasingly using mobile platforms including instant replies to questions sent by text message that doctors can use while seeing patients, ZS Associates’ Khedkar said.

Companies are investing to add more multichannel tools as doctors are increasingly pushing back on visits by sales representatives, he said. Still, that spending totals about $1 billion industrywide, compared with about $10 billion for sales-force channels, Khedkar said. The industry’s expenditure on sales-force channels has halved since 2006, he said.

Glaxo has reduced its sales force by more than 30 percent since 2009, while adding new educational roles and jobs targeting pharmacies, among others, Connelly said.

“In addition to how we operate, in terms of values and Patient First, we have a different business model today from what we had before,” she said. Those changes have helped shield Glaxo’s U.S. sales from the investigation in China, she said. The company’s U.S. pharmaceutical and vaccine sales rose 5 percent in the fourth quarter, compared with a 29 percent drop in China.

“We had done a lot before that happened,” she said. “We were fortunate that we were ready for an event like that.”

To contact the reporter on this story: Makiko Kitamura in London

To contact the editors responsible for this story: Phil Serafino Kim McLaughlin, Thomas Mulier

An Honest Psychiatrist… (1boringoldman blog)

erasing history…

Posted on Thursday 13 March 2014

You can’t really erase history, even though we all try. For one thing, it doesn’t go away. It just sits there in the background having an effect even if it has been selectively removed from consciousness. Freud made the analogy of The Mystic Writing Pad [when I was a kid, it was called the Magic Slate]. You wrote on cellophane with a stylus, When you lifted the cellophane, the writing disappeared, but it left traces in the wax below. Freud was using the metaphor to describe memory traces in the Unconscious. It was a good analogy. As a psychotherapist, one learns that it’s not like in the movies – some cave full of repressed memories. But rather, the mind just skips over or goes around unpleasant or traumatic previous experience, almost without noticing. While the gain is comfort, the loss is in not learning the important lessons that experience has to teach – so history repeats. And in eliminating chapters from the story, the book-of-you makes much less sense, because we are our stories, our narrative. What else could we be?

Right now, psychiatry seems to be attempting to erase a piece of its own history – a recent piece at that. We’ve had a couple of decades where many academic psychiatrists have been in an unholy alliance with the pharmaceutical industry, one that allowed industry to control our scientific literature, our continuing medical education, and, indeed, the whole direction of our specialty. The profits from that alliance have become the stuff of Wall Street legend – blockbusters! The ramifications of those years are everywhere around us – in our diagnostic manual, our relationships with patients and other mental health specialties, our place in the third party payment hierarchy, in the eyes of the public. As those years are finally drawing to a close, they seem to be becoming the elephant in the room that nobody’s talking about.

    • Example: Right now, the AllTrials campaign is going great guns.  Boehringer IngelheimGlaxoSmithKlineRocheSanofiViiV HealthcarePfizer, and now Johnson & Johnson are putting systems in place to allow access to their Clinical Trial data. I’ve been involved with some of the early results of that, and though it’s not a completely easy process, it’s definitely moving in the right direction towards “good enough.” But nobody’s saying why they’re doing it. They’re giving us access because they’re good guys. Nobody talks about the stream of ghost written jury-rigged decepticons that flooded our literature for a decade or more, barely disguised drug industry commercials. Nobody talks about the legal settlements that are rapidly escalating to the point where they are going to really start hurting, or the growing clamor for criminal prosecutions. They’re just being generous.
    • Example: Right now, Tom Insel is renovating the NIMH. The DSM-anything is out. The RDoC is in, when it gets around to existing. NIMH Clinical Trials have been changed. We’re on a new tack to find new drug targets. The reason the DSM-5 is out? It’s because medications and neuroscience findings don’t map onto the clinical categories. Little is mentioned about the lackey-ing around with drug trials and neuroimaging/genetics/etc. work the NIMH has funded to study and cavort with the industry’s drug output. Nothing is said about the APA/NIMH series of symposia in the lead up to the DSM-5. Not much mentioned that the Research Agenda for the DSM-V essentially laid out the RDoC agenda which came into being as it became apparent that the grand plans for the DSM-5 were going up in smoke. And there’s absolutely no comment about the fact that nothing [not even patients] map well to the DSM because it has been so distorted by outside forces.
    • Example: Dr. Lieberman [APA President] and now Dr. Summergrad [APA President Elect] can’t talk enough about something called Collaborative Psychiatry – meaning psychiatrists should work in practices with general physicians. But they don’t mention that psychiatry so bought into the psychiatrists-as-medication-prescribers model and now there are no more new meds to prescribe that they’re trying to find some kind of new identity for psychiatrists to fit into.


We did this already in 1980 – abandoned our history, whether by intent or not. One would’ve thought that the only historical figure that ever mattered was Emil Kraepelin. The psychoanalysts, Adolf Meyers, Harry Stack Sullivan, Karl Jaspers, social psychiatrists, family theorists, psychotherapists [other that CBTers] – the pantheon of psychiatrists who had contributed to our understanding of mental illness were largely forgotten and rarely mentioned in any positive way. And of interest, since the 1980s we haven’t produced any “greats” – only KOLs with a limited shelf-life.

Without our history, there is no “psychiatry.” And the current silence, particularly about our recent history, will not serve us well. Without a thorough review of the DSMs and their glitches and mistakes, who can say if Dr. Insel’s flight from clinical diagnosis into neural circuitry is a reasonable idea? And without a long look at these years of pharmaco-mania, who knows if the NIMH spending on a frantic search for new drug targets is a sound idea as opposed to some balance in the psycho· and social· arenas? And how about some new blood instead of the same old NIMH awardees getting the grants. Their history is pretty dismal. Much of what’s happening in psychiatry is a reaction to the recent past and where it has brought us. It’s the height of folly to know that’s true, and yet to talk as if that very past is off limits for serious or frank discussion, particularly the dark side…


AntiDepAware: No Justice in Bray … or Carlow

No Justice in Bray … or Carlow

From – AntiDepAware (Brilliant website created by Brian, which draws attention to dozens of cases of SSRI induced suicide, murder and related cases).

No Justice in Bray … or Carlow

Posted on March 12, 2014 by  — No Comments ↓

Yesterday morning, I was able to watch the documentary “A Search for Justice: Death in Bray”, shown the previous night on TV3 in Ireland.

SebCreaneThe programme was a powerful re-telling of the events of August 16th 2009, when 22-year-old Shane Clancy went to the house of Seb Creane (right), and stabbed him fatally. Seb was the new boyfriend of Shane’s ex-girlfriend Jen Hannigan, who was wounded by Shane in the incident, as was Seb’s older brother Dylan. Shane then went into the back garden, where he died after having stabbed himself 19 times.

ShaneClancy1Shane (left) was a popular, gregarious 22-year-old university student with no history whatsoever of violence, self-harm or mental instability of any sort. However, a few weeks before the tragedy, Shane had gone to see a doctor as he was feeling low after breaking up with Jen. He was prescribed the antidepressant Citalopram. Shane took an overdose of these tablets before he went out to buy some knives on that fateful night.

LeonieTonyLLSThe public’s interest in the case was enormous, culminating in Shane’s mother Leonie and her husband Tony being asked on to Ireland’s most popular TV programme, The Late Late Show (right). Leonie accepted the invitation on the grounds that “if this can happen to Shane it could happen to anyone – people needed to be warned.” Also on the programme was the well-respected psychiatrist Dr Michael Corry, who explained the potential dangers of SSRI antidepressants.

PatriciaCaseyLundShortly afterwards, a letter from a number of psychiatrists, led by Professor Patricia Casey (left) of University College Dublin, which expressed contrary views, was published in an Irish national newspaper. Ms Casey arrived uninvited at Shane’s inquest, but her request to contribute was declined by the coroner. Expert testimony at the inquest was provided by Dr David Healy, acknowledged as one of the world’s leading authorities in psychiatric medication. He was also completely independent, whereas Ms Casey has maintained links with Lundbeck (makers of Citalopram) over the past decade.

The jury decided that Citalopram possibly caused Shane’s death and thus recorded an open verdict. Ms Casey was not happy with this, and appeared in the media complaining about how the inquest was conducted.

Shane Clancy inquestThus Ms Casey appeared as the major proponent in the documentary, in which she clearly felt that blame for the tragedy should be directed not at the medication, but at Shane. She was given the opportunity to snipe at comments made by Dr Healy (right) in a pre-recorded interview, without Dr Healy being allowed to support his statements in reply to Ms Casey’s assertions.

JenHanniganWhat I found most extraordinary, however, was that Ms Casey felt that she was justified in diagnosing Shane merely by reading what she called his “journal” and taking sentences out of context to justify her hostile views. This “journal” was more likely to have been a collection of letters and messages sent to Jen (left). Ms Casey was also able to see and comment upon CCTV footage. With this “evidence”, Ms Casey came to the convenient conclusion that Lundbeck’s Citalopram was not responsible, but that Shane had a “depressive illness.” This in spite of the fact that Shane had no history of depression, and that he had never been diagnosed with a depressive illness during his lifetime.

This type of incident is, thankfully, very rare in Ireland. It is also rare in England and Wales, but nevertheless I have discovered over 60 antidepressant-relatedhomicides over the past 12 years. Perhaps Ms Casey would like to examine some of these cases, where she might learn something.

NigelJudithMaude2For example, Ms Casey doubted Shane’s ability to drive and to go shopping while suffering an extreme reaction to his medication. Yet, in the case of “The Perfect Couple” (right), Mr Maude stabbed to death the woman who had been the love of his life for over 25 years, then managed to drive his car from their house without incident until he reached a secluded place from where he knew he could access the main railway line unseen. There he stepped in front of a train. 16 days beforehand, Mr Maude had told his doctor that he was worried how he was going to finance his mother’s move to a care home. The doctor prescribed him antidepressants. I could also refer Ms Casey to instances where suicide victims affected by antidepressant-induced akathisia have gone shopping to buy the rope or the jerry-can full of petrol that they would use to take their lives with.

Patricia Casey has stated that: “Antidepressants do not cause suicide.” Her views are not supported the majority of her profession, nor by official bodies likeNICE or the British National Formulary in the UK, and the FDA or the NIH in the USA. They are not even supported by the pharmaceutical companies themselves, who issue (mostly inadequate) suicide warnings on their PILs.

And so to Carlow …

DeirdreKeenanLast week, an inquest heard how 53-year-old John Deegan shot dead his partner Deirdre Keenan (left), then shot himself. At the time of the incident, in February 2013, they were having a quiet weekend away in Carlow.

For those looking for reasons as to why John had acted so completely ‘out of character’, the clue came in the testimony of John’s sister, Mary Ann Molloy.

‘Just days before the tragic incident, he had called to see her and told her that his “head was bursting.”

‘She asked if he was taking his medication for depression and he said he was and when she asked if he had been drinking, he replied that he had “a couple.”’

The words above are taken directly from the online edition of the Irish Independent published at 6:58 on March 6 2014. However, by the time a lateredition had been published at 2:30 the following morning, for whatever reason,the key sentence which mentioned “medication for depression” had been removed.

JohnDeeganFuneralAt John’s funeral (right), the priest saidabout the tragedy that: “It goes beyond our comprehension.” But it shouldn’t. John’s head was bursting, he was suffering an extreme reaction to the antidepressants that he was taking. Justice in Carlow would have involved the recognition that both John and Deirdre were victims, who deserve to be mourned equally.

And as for justice in Bray, I don’t know if the programme makers feel that their “search” was fulfilled, but my version of justice would have involved an apology by the CEO of Lundbeck to the families of both Seb and Shane.

But, even if justice wasn’t achieved the other night, then at least awareness has been raised. And yesterday morning, the Irish Independent published Leonie’s call for an independent inquiry into the effects of SSRIs. I don’t expect it to happen, but at least a significant number of people who had never heard of Citalopram until this week will now be aware of the destructive potential of this mind-altering medication.